Human Papillomavirus (HPV) Vaccine

Two vaccines to protect against human papilloma viruses (HPV) have been developed.  The first to be licensed, Gardasil, produced by Merck protects against four HPV types including the two types most commonly associated with cervical cancer (types 16 and 18) and the two types that cause most genital warts (types 6 and 11). An application has been submitted by Glaxo SmithKline for another HPV vaccine and licensure is expected either later in 2008 or early 2009.

Both of these vaccines have been shown to be highly efficacious for protection against persistent infections with the serotypes that are in the vaccines.  The most common side effects have been local pain and fainting. Rare allergic reactions have been reported as well.

• Gardasil Vaccine Reports to VAERS - link to CDC site
• HPV Vaccine Q&A - link to CDC
• American Social Health Association page on HPV and Cervical Cancer Prevention - link to ashastd.org
• Cervical Cancer: Fast Facts - link to ivillage.com
• American Cancer Society Recommendations for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Pre-Cancers - link
   

This page was last updated on May 19, 2008

© 2008 Institute for Vaccine Safety